Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when

Purpose This review discusses the role of bacterial adjuvants and antigens in induction and reactivation of chronic intestinal inflammation in susceptible hosts; discusses the results of recent therapeutic trials of antibiotics, probiotics, and prebiotics; and suggests future treatment strategies. Recent findings Bacterial adjuvants, including peptidoglycan, lipopolysaccharide, and DNA (CpG) bind to membrane‐bound toll‐like receptors (TLR‐2, 4, and 9. respectively) or cytoplasmic (NOD1 and NOD2) receptors (pattern recognition receptors) that activate nuclear factor‐&kgr;B and transcription of many proinflammatory cytokines and adhesion, costimulatory, and major histocompatibility complex class II molecules. Experimental enterocolitis does not occur in a sterile (germ‐free) environment and is prevented and treated by broad‐spectrum antibiotics. Individual nonpathogenic intestinal bacterial species selectively induce experimental colitis, with host specificity. Crohn disease and ulcerative colitis patients exhibit pathogenic immune responses (loss of immunologic tolerance) to multiple normal enteric bacterial species and serologic responses to Mycobacterium paratuberculosis. Metronidazole and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperative Crohn disease. Certain probiotic species decrease relapse of ulcerative colitis and chronic pouchitis and delay onset of pouchitis. Summary Normal, nonpathogenic enteric bacteria induce and perpetuate chronic intestinal inflammation in genetically susceptible hosts with defective immunoregulation, bacterial clearance, or mucosal barrier function. Altering the composition and decreasing mucosal adherence/invasion of commensal bacteria with antibiotics, probiotics, and prebiotics can potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative colitis, but optimal treatments have not yet been identified.

[1]  Lillian Maggio-Price,et al.  Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. , 2002, The American journal of pathology.

[2]  R. Medzhitov,et al.  Toll-like receptors and their ligands. , 2002, Current topics in microbiology and immunology.

[3]  C. O'Morain,et al.  CARD4/NOD1 is not involved in inflammatory bowel disease , 2003, Gut.

[4]  C. Neut,et al.  Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease , 2002, American Journal of Gastroenterology.

[5]  C. Moskaluk,et al.  Down-Regulation of Intestinal Lymphocyte Activation and Th1 Cytokine Production by Antibiotic Therapy in a Murine Model of Crohn’s Disease1 , 2002, The Journal of Immunology.

[6]  J. Schölmerich,et al.  Different Subsets of Enteric Bacteria Induce and Perpetuate Experimental Colitis in Rats and Mice , 2001, Infection and Immunity.

[7]  H. Järvinen,et al.  Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora , 2003, Alimentary pharmacology & therapeutics.

[8]  G. Gould,et al.  Pasteurization of milk and the heat resistance of Mycobacterium avium subsp. paratuberculosis: a critical review of the data. , 2002, International journal of food microbiology.

[9]  M. Palkovits,et al.  Gastric acid secretion in L-histidine decarboxylase-deficient mice. , 2002, Gastroenterology.

[10]  K. Petraki,et al.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. , 2001, Scandinavian journal of gastroenterology.

[11]  S. Pawlowski,et al.  Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. , 2002, Cancer research.

[12]  P. Gionchetti,et al.  VSL3 probiotic mixture induces remission in patients with active ulcerative colitis , 2003 .

[13]  J. Rodés,et al.  5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. , 2002, Gastroenterology.

[14]  H. Glise,et al.  The role of the gut flora in health and disease, and its modification as therapy , 2002, Alimentary pharmacology & therapeutics.

[15]  R. Bibiloni,et al.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis , 2005, The American Journal of Gastroenterology.

[16]  A. Cohen,et al.  Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. , 2001, Gastroenterology.

[17]  P. Gionchetti,et al.  Probiotics--role in inflammatory bowel disease. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  M. Sata,et al.  Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. , 2001, International journal of molecular medicine.

[19]  R. Sartor,et al.  Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice , 1998, Infection and Immunity.

[20]  S. Naser,et al.  Seroreactivities Against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 Antigens in Crohn's Disease Patients , 2002, Digestive Diseases and Sciences.

[21]  P. Brigidi,et al.  Prophylaxis of pouchitis onset with probiotic therapy: A double‐blind, placebo‐controlled trial , 2000, Gastroenterology.

[22]  Jonathan Braun,et al.  Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. , 2002, Gastroenterology.

[23]  F. Guarner,et al.  Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat , 2001, American Journal of Gastroenterology.

[24]  C. O'Morain,et al.  CARD 4 / NOD 1 is not involved in inflammatory bowel disease , 2002 .

[25]  H. Redmond,et al.  Sulfate-Reducing Bacteria Colonize Pouches Formed for Ulcerative Colitis but Not for Familial Adenomatous Polyposis , 2002, Diseases of the colon and rectum.

[26]  C. Jobin,et al.  Butyrate modulates intestinal epithelial cell‐mediated neutrophil migration , 2003, Clinical and experimental immunology.

[27]  Meijia Yang,et al.  A novel human fibroblast growth factor treats experimental intestinal inflammation. , 2002, Gastroenterology.

[28]  F. Shanahan,et al.  PCR detection of Mycobacterium paratuberculosis in Crohn’s disease granulomas isolated by laser capture microdissection , 2002, Gut.

[29]  C. Folwaczny,et al.  A Polymorphism in the CD14 Gene is Associated with Crohn Disease , 2002, Scandinavian journal of gastroenterology.

[30]  T. Borody,et al.  Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure? , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[31]  P. Rutgeerts,et al.  Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease , 2002, American Journal of Gastroenterology.

[32]  P. Gionchetti,et al.  Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment , 2001, American Journal of Gastroenterology.

[33]  R. Sartor,et al.  Lactobacillus plantarum 299V in the Treatment and Prevention of Spontaneous Colitis in Interleukin-10-Deficient Mice , 2002, Inflammatory bowel diseases.

[34]  S. Naser,et al.  Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[35]  R. Sartor,et al.  Regional and host specificity of colitis in mice monoassociated with different non-pathogenic bacteria , 2003 .

[36]  C. Elson,et al.  Bacterial-Reactive T Regulatory Cells Inhibit Pathogenic Immune Responses to the Enteric Flora1 , 2002, The Journal of Immunology.

[37]  T. Warner,et al.  Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. , 2002, The American journal of pathology.

[38]  A. Sher,et al.  Bacteria-triggered CD4+ T Regulatory Cells Suppress Helicobacter hepaticus–induced Colitis , 2002, The Journal of experimental medicine.

[39]  Jongdae Lee,et al.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.

[40]  T. Bull,et al.  Crohn's disease caused by Mycobacterium avium subspecies paratuberculosis: a public health tragedy whose resolution is long overdue. , 2002, Journal of medical microbiology.

[41]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[42]  Judy H. Cho,et al.  Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. , 2003, Gastroenterology.

[43]  M. Abreu,et al.  TLR4 and MD-2 Expression Is Regulated by Immune-mediated Signals in Human Intestinal Epithelial Cells* , 2002, The Journal of Biological Chemistry.

[44]  R. Sartor,et al.  Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment , 2000, Gut.

[45]  T. Ohkusa,et al.  Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species‐specific antibody , 2002, Journal of gastroenterology and hepatology.

[46]  H. Hooijkaas,et al.  Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods , 2002, European journal of gastroenterology & hepatology.

[47]  N. Borruel,et al.  Increased mucosal tumour necrosis factor α production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria , 2002, Gut.

[48]  M. Blaser.  Probiotics and Prebiotics: Where Are We Going? , 2003, Emerging Infectious Diseases.

[49]  D. Mishkin,et al.  The Glucose Breath Test: A Diagnostic Test for Small Bowel Stricture(s) in Crohn's Disease , 2002, Digestive Diseases and Sciences.

[50]  P. Rosenstiel,et al.  TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells ☆ ☆☆ ★ ★★ ♢ , 2003 .

[51]  D. Podolsky,et al.  CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. , 2003, Gastroenterology.

[52]  D. Haller,et al.  IKKβ and Phosphatidylinositol 3-Kinase/Akt Participate in Non-pathogenic Gram-negative Enteric Bacteria-induced RelA Phosphorylation and NF-κB Activation in Both Primary and Intestinal Epithelial Cell Lines* , 2002, The Journal of Biological Chemistry.

[53]  R. Farrell,et al.  Microbial factors in inflammatory bowel disease. , 2002, Gastroenterology clinics of North America.

[54]  C. Prantera,et al.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG , 2002, Gut.

[55]  N. Barnich,et al.  Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. , 1998, Gastroenterology.

[56]  S. Naser,et al.  In situ identification of mycobacteria in Crohn's disease patient tissue using confocal scanning laser microscopy. , 2002, Molecular and cellular probes.

[57]  M. Blaut,et al.  Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora , 2001, British Journal of Nutrition.

[58]  P. Brigidi,et al.  Effects of Rifaximin Administration on the Intestinal Microbiota in Patients with Ulcerative Colitis , 2002, Journal of chemotherapy.

[59]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[60]  S. Weiss,et al.  Eat dirt--the hygiene hypothesis and allergic diseases. , 2002, The New England journal of medicine.

[61]  M. Kamm,et al.  Use of Probiotics in the Treatment of Inflammatory Bowel Disease , 2003, Journal of clinical gastroenterology.

[62]  Yasunori Ogura,et al.  Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation* , 2002, The Journal of Biological Chemistry.

[63]  J. Achkar,et al.  A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis , 2001, Inflammatory bowel diseases.

[64]  Manfred Dietel,et al.  Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.

[65]  K. Wilson,et al.  Differential Induction of Colitis and Gastritis in HLA-B27 Transgenic Rats Selectively Colonized with Bacteroides vulgatus or Escherichia coli , 1999, Infection and Immunity.

[66]  G. Arnold,et al.  Preliminary Study of Ciprofloxacin in Active Crohn's Disease , 2002, Inflammatory bowel diseases.

[67]  R. Sartor,et al.  Helicobacter hepaticus Does Not Induce or Potentiate Colitis in Interleukin-10-Deficient Mice , 2000, Infection and Immunity.